Human IFN‑ alpha Antibody

Name: Human IFN‑ alpha Antibody
Brand: R&D Systems
SKU: 31101-1
Price: 369 USD
Availability: InStock

R&D Systems | Catalog # 31101-1

Submit a review

Citations (3)

Product Documents

100% Guarantee

Product Specifications
Applications
Preparation & Storage
Background
Product Documents
Specific Notices
Research Areas
Related Blogs

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Mouse

Applications

Validated:

Neutralization

Cited:

ELISA Development

Label

Unconjugated

Antibody Source

Polyclonal Rabbit Serum

View all IFN-alpha Primary Antibodies »

Product Specifications

Immunogen

E. coli-derived recombinant human IFN-alpha

Specificity

Human IFN-alpha

Clonality

Polyclonal

Host

Rabbit

Isotype

Serum

Applications for Human IFN‑ alpha Antibody

Application

Recommended Usage

Neutralization

One neutralization unit is the amount of antiserum required to neutralize one unit of human interferon alpha (Hu-IFN-alpha ) to a 50% endpoint. Interferon was titrated with the use of the cytopathic effect inhibition assay [Rubinstein, S., Familletti, P.C., and Pestka, S. (1981) J. Virol. 37, 755-758] using A549 cells and EMCV was used as the challenge virus [Budd et al. (1985) Canc. Chem. Pharm. 12:39]. In this antiviral assay for interferon, about 1 unit/ml of interferon is the quantity necessary to produce a cytopathic effect of 50%. The units are determined by use of a laboratory standard calibrated with respect to the international reference standard for Hu-IFN-alpha provided by the National Institutes of Health [Gxa01-901-535]. This material is prepared specifically for effective neutralization of Hu-IFN-alpha.

Formulation, Preparation, and Storage

Shipping

The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

After receipt, the product may be stored at -20°C for short-term use (≤ 6 months). For long-term storage, we recommend storing the product at -70°C or below for retention of full activity. When thawing, the contents of the tube should be apportioned in separate tubes so that freezing and thawing is kept to a minimum. Refreezing should be done on dry ice or in a dry ice/alcohol bath. Further dilution of the product should be in buffers containing protein such as 0.1% bovine serum albumin (BSA).

Background: IFN-alpha

The most common use of this product has been in a pool with Rabbit Anti-Human Interferon Beta (PBL # 31410) and Mouse Anti-IFNAR2 (PBL# 21385) to block the activity of all Type I IFNs. Krug et al [Eur. J. Immunol. (2001) 31:2154] used a pool of PBL #31101, #31410 and #21385 to demonstrate PBMC-derived Type I IFN is responsible for increased IFN-gamma secretion after stimulation with CpG ODN. Ito et al. [J. Exp. Med. (2002) 195:1507] used a similar pool to determine that TLR7 stimulated pDC but not mDC induce Th1 development through Type I IFN. Lande et al. [J. Immunol. (2003) 170:1174] used a pool of PBL#31410 and #31101 to show a blockade of autocrine Alpha/Beta action leads to decreased CXCL-10 secretion from Mycobacterium-infected dendritic cells. Jego et al. [Immunity (2003) 19:225] demonstrated the inhibition of IFN-alpha signaling in a co-culture of pDCs with CD40 stimulated B-cells reduces IgG secretion, while inhibition of IFN-beta signaling does not occur. Ku et al. [J. Exp. Med. (2004) 200:917] showed epithelial cells surrounding Varicella Zoster lesions express IFN-alpha by immunohistochemistry (IHC) in a SCID-human skin zenograft model.